All In MedTech

FDA Clearance Tracker · P140008-S025

ORBERA Intragastric Balloon (IGB) System, Endoline Punc

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 14, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 14, 2023

Approved

Time to decision

73 days

Received Oct 2, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P140008-S025
Device name
ORBERA Intragastric Balloon (IGB) System, Endoline Punc
Applicant location
Marlboro, MA
Received
Oct 2, 2023
Decided
Dec 14, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P140008

Device type

Device class
Class III

Every decision under product code LTI

FDA's approval statement

As written in FDA's record.

approval for the inclusion of the Prince Medical deflation needle to puncture and drain the ORBERA Intragastric Balloon (IGB) System during removal, thereby addressing a classification issue identified by FDA

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.